P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A

• F. Xue,
• X. Zhao,
• J. Sun,
• X. Zeng,
• F. Yang,
• M. Xu,
• Z. Yu,
• W. Gu,
• Y. Feng,
• W. Li,
• C. Zheng,
• H. Bi,
• C. Ma,
• W. Gai,
• L. Xie,
• R. Yang

Affiliations

F. Xue

1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

X. Zhao

2 Xiangya Hospital Central South University, Changsha

J. Sun

3 Nanfang Hospital Affiliated to Southern Medical University, Guangzhou

X. Zeng

4 The affiliated Hospital of Guizhou Medical University, Guizhou

F. Yang

5 Fujian Medical University Union Hospital, Fuzhou

M. Xu

6 Chengdu Women’s & Children’s Central Hospital, Chengdu

Z. Yu

7 The First Affiliated Hospital of Soochou University, Suzhou

W. Gu

8 he First People’s Hospital of Changzhou, Changzhou

Y. Feng

9 The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

W. Li

10 Qinghai Provincial People’s Hospital, Xining

C. Zheng

11 Anhui Provincial Hospital, Hefei

H. Bi

12 The Second Affiliated Hospital of Kunming Medical University, Kunming

C. Ma

13 Sinocelltech Ltd., Beijing, China

W. Gai

13 Sinocelltech Ltd., Beijing, China

L. Xie

13 Sinocelltech Ltd., Beijing, China

R. Yang

1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin